Shots: The BT designation is based on part B of the P-I study assessing Magrolimab + Azacitidine in 33 previously untreated intermediate, high, and very high-risk MDS patients. The results […]readmore
Tags : Myelodysplastic Syndrome
Shots: The FDA’s BT designation is based on MDS arm of P-I dose-escalation and expansion study assessing Tibsovo (500mg) in 12 patients with r/r MDS with a susceptible IDH1 mutation […]readmore